Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Caladrius Biosciences, Inc. (CLBS)

0.4264   -0.086 (-16.75%) 09-15 00:00
Open: 0.648 Pre. Close: 0.5122
High: 0.6497 Low: 0.382
Volume: 26,946,654 Market Cap: 3(M)

Technical analysis

as of: 2022-11-18 4:19:29 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 3.47     One year: 5.34
Support: Support1: 0.38    Support2: 0.31
Resistance: Resistance1: 2.97    Resistance2: 4.57
Pivot: 0.69
Moving Average: MA(5): 0.42     MA(20): 1.54
MA(100): 5.58     MA(250): 8.41
MACD: MACD(12,26): -1.1     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 1     %D(3): 1
RSI: RSI(14): 19.9
52-week: High: 17.09  Low: 0.38
Average Vol(K): 3-Month: 6,796 (K)  10-Days: 26,947 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CLBS ] has closed above bottom band by 43.3%. Bollinger Bands are 2.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.65 - 0.65 0.65 - 0.66
Low: 0.38 - 0.38 0.38 - 0.38
Close: 0.42 - 0.43 0.43 - 0.43

Company Description

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Headline News

Wed, 14 Sep 2022
Caladrius Biosciences Announces Approval of Merger and Name ... - GlobeNewswire

Thu, 09 Jun 2022
Cend Therapeutics Announces First Patient Treated in Phase 2b ... - GlobeNewswire

Thu, 26 May 2022
Caladrius Biosciences and Cend Therapeutics Announce Poster ... - GlobeNewswire

Wed, 27 Apr 2022
CLBS stock surges on merger with Cend Therapeutics (NASDAQ ... - Seeking Alpha

Wed, 27 Apr 2022
Caladrius Biosciences and Cend Therapeutics Announce Definitive ... - GlobeNewswire

Wed, 20 Jan 2021
Penny Stocks Are Red Hot But Is Now The Right Time To Buy? - Penny Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 60 (M)
Shares Float 59 (M)
% Held by Insiders 2.7 (%)
% Held by Institutions 18.5 (%)
Shares Short 544 (K)
Shares Short P.Month 564 (K)

Stock Financials

EPS -0.53
EPS Est Next Qtl -0.77
EPS Est This Year -2.43
EPS Est Next Year -2.96
Book Value (p.s.) 1.67
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.8
Return on Equity (ttm) -23.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.47
Qtrly Earnings Growth 0
Operating Cash Flow -20 (M)
Levered Free Cash Flow -16 (M)

Stock Valuations

PE Ratio -0.81
PEG Ratio -0.1
Price to Book value 0.25
Price to Sales 0
Price to Cash Flow -1.29

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2016-07-27
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.